For: | Krivtsova O, Makarova A, Lazarevich N. Aberrant expression of alternative isoforms of transcription factors in hepatocellular carcinoma. World J Hepatol 2018; 10(10): 645-661 [PMID: 30386458 DOI: 10.4254/wjh.v10.i10.645] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v10/i10/645.htm |
Number | Citing Articles |
1 |
Suchita Dattatray Shinde, Neeraj Kulkarni, Bichismita Sahu, Kiran Kalia, Santosh Kumar Behera. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2. 2022; : 149 doi: 10.1016/B978-0-323-98807-0.00007-7
|
2 |
Mikhail S. Chesnokov, Anil Yadav, Ilana Chefetz. Optimized Transcriptional Signature for Evaluation of MEK/ERK Pathway Baseline Activity and Long-Term Modulations in Ovarian Cancer. International Journal of Molecular Sciences 2022; 23(21): 13365 doi: 10.3390/ijms232113365
|
3 |
Erzsébet Rásó. Splice variants of RAS—translational significance. Cancer and Metastasis Reviews 2020; 39(4): 1039 doi: 10.1007/s10555-020-09920-8
|
4 |
Ruth Nussinov, Chung-Jung Tsai, Hyunbum Jang. How can same-gene mutations promote both cancer and developmental disorders?. Science Advances 2022; 8(2) doi: 10.1126/sciadv.abm2059
|
5 |
Deborah P. Lavin, Vijay K. Tiwari. Unresolved Complexity in the Gene Regulatory Network Underlying EMT. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.00554
|